BACKGROUND: The study of cochlear health (CH) has several applications, including explaining variation in CI outcomes, informing CI programming strategies, and evaluating the safety and efficacy of novel biological treatments for hearing loss. Very early postoperative CH patterns have not previously been intensively explored through longitudinal daily testing. Thanks to technological advances, electrode impedances, eCAPs, and ECochGs can be independently performed by CI users at home to monitor CH over time.
METHODS: A group of newly implanted CI users performed daily impedances, eCAPs, and ECochGs for 3 months at home, starting from the first day postsurgery (N = 7) using the Active Insertion Monitoring system by Advanced Bionics.
RESULTS: Measurement validity of 93.5, 93.0, and 81.6% for impedances, eCAPs, and ECochGs, respectively, revealed high participant compliance. Impedances increased postsurgery before dropping and stabilizing after switch-on. eCAPs showed good stability, though statistical analyses revealed a very small but significant increase in thresholds over time. Most ECochG thresholds did not reach the liberal signal-to-noise criterion of 2:1, with low threshold stability over time.
CONCLUSIONS: Newly implanted CI recipients can confidently and successfully perform CH recordings at home, highlighting the valuable role of patients in longitudinal data collection. Electrode impedances and eCAPs are promising objective measurements for evaluating CH in newly implanted CI users.
背景:对耳蜗健康(CH)的研究有多种应用,包括解释CI结果中的变异,informingCI编程策略,并评估新型生物治疗听力损失的安全性和有效性。先前尚未通过纵向每日测试对非常早期的术后CH模式进行深入研究。由于技术的进步,电极阻抗,eCAPs,和ECochG可以由CI用户在家中独立执行以随时间监视CH。
方法:一组新植入的CI用户每天进行阻抗,eCAPs,和ECochGs在家三个月,从术后第一天开始(N=7),使用高级仿生学的主动插入监测系统。
结果:阻抗的测量有效性分别为93.5、93.0和81.6%,eCAPs,和ECochGs,分别,显示参与者的高合规性。手术后的阻抗增加,然后下降并在接通后稳定。eCAPs表现出良好的稳定性,尽管统计分析显示,随着时间的推移,阈值有非常小但显著的增加。大多数ECochG阈值未达到2:1的自由信噪比标准,随着时间的推移,阈值稳定性较低。
结论:新植入的CI接受者可以在家中自信而成功地进行CH录音,强调患者在纵向数据收集中的重要作用。电极阻抗和eCAP是有前途的客观测量,可用于评估新植入的CI用户的CH。